drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Humanized anti-HER2 IgG1 monoclonal antibody that binds domain IV of ERBB2, inhibits HER2 signaling, and mediates ADCC.
nci_thesaurus_concept_id
C1647
nci_thesaurus_preferred_term
Trastuzumab
nci_thesaurus_definition
A recombinant humanized monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). After binding to HER2 on the tumor cell surface, trastuzumab induces an antibody-dependent cell-mediated cytotoxicity against tumor cells that overexpress HER2. HER2 is overexpressed by many adenocarcinomas, particularly breast adenocarcinomas. (NCI04)
drug_mesh_term
Trastuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting HER2/ERBB2 (binds domain IV) on tumor cells; inhibits HER2 signaling and downstream PI3K/AKT and MAPK pathways, reduces receptor activation, and mediates immune effector killing via antibody-dependent cellular cytotoxicity (ADCC).
drug_name
Trastuzumab
nct_id_drug_ref
NCT06162559